Villanova University is very excited to be launching this new research center in a region that has played a central role in the discovery and manufacture of two recently (FDA) approved ground breaking cell/gene therapy products: Novartis’ KYMRIAH and Luxturna by Spark Therapeutics.
NovaCell is focused on personalized medicine, especially for the immune system. Our ongoing research will help to improve the capture, transfection and growth of the CAR-T-cell bio manufacture process. In addition, CART therapy is a type of personalized medicine that requires manufacturing companies to connect more directly to the patients than with traditional treatments. This new research center will provide a unique opportunity for student and faculty researchers to gain experience interacting with doctors and, potentially, patients as well. This concept embodies one of Villanova’s core, mission-related commitments: to encourage our students and faculty to pursue virtue by integrating love (Caritas) and knowledge (or truth; Veritas), and by committing themselves to research and education, with “special compassion for the suffering."
Dr. William J. Kelly
Director of NovaCell (Center for Cellular Engineering)